• Explore /
  • Poster
  • / A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

Abstract Poster

Authors

R. Donald Harvey

R. Donald Harvey

Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA

R. Donald Harvey , Joseph Franz , Nisha S Joseph , Jonathan L. Kaufman , Elise Hitron , Hannah Collins , Catherine Braga , Kathryn T. Maples , Craig C. Hofmeister , Madhav V. Dhodapkar , Sagar Lonial , Ajay K. Nooka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04352205

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8057)

DOI

10.1200/JCO.2023.41.16_suppl.8057

Abstract #

8057

Poster Bd #

49

Abstract Disclosures

Similar Posters

First Author: Andrew Jenho Yee

First Author: Saad Zafar Usmani

First Author: Cristina Gasparetto

First Author: Meletios A. Dimopoulos